The interview began at 2 p.m., and [Jim] Grant went straight after the elephant in the room — the Valeant-Allergan deal. "May I call you Bill, or do you prefer 'Alpha'?" Grant asked playfully before launching into a series of questions. Before we go any further into this story, you should know that short-seller Jim Chanos, CEO of Kynikos Associates, was sitting in the crowd. Chanos is famously short Valeant. He says it is an accounting rollup that lacks organic growth. Ackman knew Chanos was in the crowd, because during the lunch lecture (about 20 minutes before Ackman's interview), Chanos asked a question in front of everyone present. Now, back to Ackman's interview. As Grant asked the same questions about Valeant-Allergan that critics have been asking for months — "Does the company actually make money?" "Does Valeant overpay for its acquisitions?" "Doesn't it need to spend money on R&D?" — Ackman started to bristle a bit. Suddenly, he turned toward Grant. "Are you short because your daughter is working for Jim Chanos?" he asked pointedly. [BI]
Bill Ackman Doesn't Think Valeant's Awesomeness Has Been Adequately Conveyed
There's simply no other way to explain what's happening there.
Bill Ackman Gets The 'Last Days In The Bunker' Treatment
The hits just keep on coming.